RCS - Verici Dx PLC - Medicare National Payment Rate Confirmation

Verici DxAnnouncement

08/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240108:nRSH8695Ya&default-theme=true

RNS Number : 8695Y  Verici Dx PLC  08 January 2024

Verici Dx plc

("Verici Dx" or the "Company")

 

Medicare National Payment Rate for Tutivia™ and Clarava™ Effective as of
January 1, 2024

CMS finalises gapfill median rate at $2,650 per test

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that the Centers for Medicare & Medicaid
Services ("CMS") released the Clinical Laboratory Fee Schedule ("CLFS")
payment rate of $2,650 established through the "gapfill" process for both
Tutivia™ (CPT 0320U), its post-transplant test focused upon acute cellular
rejection, and Clarava™ (CPT 0319U), its pre-transplant prognosis test for
the risk of early acute rejection. This rate is effective as of January 1,
2024.

Having a national payment rate established by CMS represents a step toward
securing reimbursement for testing by Medicare, a national health insurance
program in the US that covers 63.9 million patients. Gapfill pricing is a
method used by CMS to establish a payment rate for clinical diagnostic
laboratory tests when no comparable test is priced on the CLFS and involves
setting the payment rate for the test at the median of rates established by
local Medicare contractors.

Sara Barrington, Chief Executive Officer of Verici Dx, commented: "We are
pleased that the pricing for both Tutivia™ and Clarava™ has been confirmed
and finalised at the proposed rates. This is another important milestone in
our strategy to develop and commercialise a complementary suite of
ground-breaking products that offer end-to-end testing for kidney transplant
patients and their clinicians."

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Sam Butcher / Jalini Kalaravy

 Walbrook PR Limited                                      Tel: 020 7933 8780 or vericidx@walbrookpr.com
                                                          (mailto:renalytix@walbrookpr.com)
 Stephanie Cuthbert / Sam Allen                           Mob: 07796 794 663 / 07502 558 258

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes.  The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage.  The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADBGDBCXGDGSR